Praktické lekárnictvo 1-2/2020

Do CGRPs monoclonal antibodies represent a progress in the prophylaxis of migraine?

Migraine is a neurological disease that significantly reduces the quality of life of patients. According to statistics, its incidence is high, it is reported to be the third most common disease. Migraine is often underdiagnosed, misdiagnosed and treated incorrectly. Analgesics, non-steroidal anti-inflammatory drugs, triptans and drugs from other pharmacological groups are used in therapy. The available treatment is in many cases unsatisfactory. In recent years, research has focused on influencing pain and vasodilation through blockade of the calcitonin gene-related peptide (CGRP) or its receptor.

Keywords: migraine, acute, chronic and preventive treatment, CGRP monoclonal antibodies.